China-based firm Overland Pharmaceuticals has entered into a strategic partnership with GoBroad Healthcare Group to enhance Overland’s translational and clinical study capabilities in the cell therapy field. The collaboration aims to strengthen Overland’s development efforts in universal chimeric antigen receptor (CAR)-T cell therapy. No financial details were disclosed.
Scope of the Partnership
Overland Pharma, which is focused on the development of universal CAR-T cell therapies, expects GoBroad to provide a comprehensive range of clinical research services. These include clinical research resource planning, registered medical strategy, project management, clinical operation, data management, statistical analysis, third-party audit, pharmacovigilance, medical supervision, central laboratory Core-Lab, central imaging IRC, and other clinical research services.
Significance of the Collaboration
This strategic partnership will significantly bolster Overland Pharmaceuticals’ ability to advance its cell therapy initiatives. By leveraging GoBroad Healthcare’s expertise and resources, Overland aims to accelerate the development and commercialization of innovative cell therapies, ultimately improving patient outcomes and expanding its presence in the healthcare market.-Fineline Info & Tech
